TB vaccine hopes fade
Wednesday, February 6th, 2013
A major trial of a tuberculosis (TB) vaccine has ended in failure, marking a major setback in the fight against the disease, which cause 1.4 million deaths a year.
The latest vaccine, known as MVA85A, failed to protect babies who had already had the Bacillus Calmette-Guerin (BCG), the BBC reported.
BCG is only partially effective against the bacterium that causes TB, which is why several international teams are working on new vaccines.
The trial, in South Africa, involved 2,794 healthy children aged four to six months, half of whom received MVA85A and the rest a placebo.
They were followed up for an average of two years.
The researchers found 32 cases of TB in those who had received the vaccine compared with 39 in the placebo group.
This gave an effectiveness of 17 percent, which is so low as to be statistically non-significant.
In a new study, researchers have identified the chemical fingerprints given off by specific bacteria when present in the lungs, potentially allowing for a quick and simple breath test to diagnose infections such as tuberculosis.
Chennai: Apollo Hospitals along with Indian Medical Association organized a Continuing Medical Education (CME) program to inform medical practitioners on the advanced medical treatment options available.
Anyone with a weak immune system is susceptible for tuberculosis (TB) in certain situations. These situations are malnutrition, diabetes, renal failure, long term drug/alcohol abuse, HIV/AIDS, chemotherapy for cancer, old age and living in unsanitary crowded places.